Background
The molecular signature of atopic dermatitis/AD lesions is associated with Th2 and Th22 activation, and epidermal alterations. However, the epidermal and dermal AD transcriptomes and their respective contributions to abnormalities in respective immune and barrier phenotypes are unknown.
Objective
To establish the genomic profile of the epidermal and dermal compartments of lesional/LS and non-lesional/NL AD, as compared with normal skin.
Methods
Laser capture micro-dissection/LCM was performed to separate epidermis and dermis of LS and NL skin from AD patients and normal skin from healthy volunteers followed by gene expression (microarrays and RT-PCR) and immunostaining studies.
Results
Our study identified novel immune and barrier genes, including the IL-34 cytokine and claudins 4 and 8, and showed increased detection of key AD genes usually undetectable on arrays (i.e. IL-22, TSLP, CCL22, and CCL26). Overall, the combined epidermal and dermal transcriptomes enlarged the AD transcriptome adding 674 up-regulated and 405 down-regulated differentially expressed genes between LS and NL skin to the AD transcriptome. We were also able to localize individual transcripts as primarily epidermal (DEFB4A) or dermal (IL-22, CTLA4, and CCR7), and link their expressions to possible cellular sources.
Conclusions
This is the first report that establishes robust epidermal and dermal genomic signatures of LS, NL AD and normal/N skin, as compared with whole tissues. These data establish the utility of LCM to separate different compartments and cellular subsets in AD, allowing localization of key barrier or immune molecules, and enable detection of gene products usually not detected on arrays.
BackgroundAtopic dermatitis (AD) is a common inflammatory skin disease with limited treatment options. Several microarray experiments have been conducted on lesional/LS and non-lesional/NL AD skin to develop a genomic disease phenotype. Although these experiments have shed light on disease pathology, inter-study comparisons reveal large differences in resulting sets of differentially expressed genes (DEGs), limiting the utility of direct comparisons across studies.MethodsWe carried out a meta-analysis combining 4 published AD datasets to define a robust disease profile, termed meta-analysis derived AD (MADAD) transcriptome.ResultsThis transcriptome enriches key AD pathways more than the individual studies, and associates AD with novel pathways, such as atherosclerosis signaling (IL-37, selectin E/SELE). We identified wide lipid abnormalities and, for the first time in vivo, correlated Th2 immune activation with downregulation of key epidermal lipids (FA2H, FAR2, ELOVL3), emphasizing the role of cytokines on the barrier disruption in AD. Key AD “classifier genes” discriminate lesional from nonlesional skin, and may evaluate therapeutic responses.ConclusionsOur meta-analysis provides novel and powerful insights into AD disease pathology, and reinforces the concept of AD as a systemic disease.Electronic supplementary materialThe online version of this article (doi:10.1186/s12920-015-0133-x) contains supplementary material, which is available to authorized users.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.